EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments

Jianda Yue, Yekui Yin, Xujun Feng, Jiawei Xu, Yaqi Li iD, Tingting Li, Songping Liang, Xiao He iD, Zhonghua Liu, Ying Wang iD

International Journal of Molecular Sciences · 29.07.2024 · 25 (15) · 8284

DOI: 10.3390/ijms25158284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.07.2024. Verfasst von Jianda Yue und 9 weiteren Autor:innen. Beteiligte Einrichtung: The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha 4…. Hauptthemen laut MEDLINE: Amino Acid Transport System y+, Glutathione, Molecular Dynamics Simulation, Reactive Oxygen Species. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Procinve, Science and Technology Innovation Program of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the development and progression of cervical cancer, oxidative stress plays an important role within the cells. Among them, Solute Carrier Family 7 Member 11 (SLC7A11/xCT) is crucial for maintaining the synthesis of glutathione and the antioxidant system in cervical cancer cells. In various tumor cells, studies have shown that SLC7A11 inhibits ferroptosis, a form of cell death, by mediating cystine uptake and maintaining glutathione synthesis. Additionally, SLC7A11 is also involved in promoting tumor metastasis and immune evasion. Therefore, inhibiting the SLC7A11/xCT axis has become a potential therapeutic strategy for cervical cancer. In this study, through structure-based high-throughput virtual screening, a compound targeting the SLC7A11/xCT axis named compound 1 (PubChem CID: 3492258) was discovered. In vitro experiments using HeLa cervical cancer cells as the experimental cell model showed that compound 1 could reduce intracellular glutathione levels, increase glutamate and reactive oxygen species (ROS) levels, disrupt the oxidative balance within HeLa cells, and induce cell death. Furthermore, molecular dynamics simulation results showed that compound 1 has a stronger binding affinity with SLC7A11 compared to the positive control erastin. Overall, all the results mentioned above indicate the potential of compound 1 in targeting the SLC7A11/xCT axis and treating cervical cancer both in vitro and in silico.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino Acid Transport System y+GlutathioneMolecular Dynamics SimulationReactive Oxygen SpeciesUterine Cervical NeoplasmsHumansHeLa CellsOxidative StressMolecular Docking SimulationFemaleDrug DiscoveryAntineoplastic AgentsComputer SimulationFerroptosis

Stichwörter der Autor:innen

SLC7A11/xCT axiscervical cancerdrug discoveryoxidative stressvirtual screening and molecular dynamics simulation

Substanzen

SLC7A11 protein, humanAmino Acid Transport System y+GlutathioneReactive Oxygen SpeciesAntineoplastic Agents

Autor:innen und Institutionen

  • The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha 410081, China.
  • Peptide and Small Molecule Drug R&D Plateform, Furong Laboratory, Hunan Normal University, Changsha 410081, China.
  • Institute of Interdisciplinary Studies, Hunan Normal University, Changsha 410081, China.
  • Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
  • Shanghai Frontiers Science Center of Molecule Intelligent Syntheses, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
  • New York University-East China Normal University Center for Computational Chemistry, New York University Shanghai, Shanghai 200062, China.

ORCID-Profile: Yaqi Li, Xiao He, Ying Wang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Procinve
  • Science and Technology Innovation Program of Hunan Province
  • Scientific Research Program of FuRong Laboratory
  • Scientific research project of Department of Education of Hunan Province
  • Natural Science Foundation of Hunan Province
  • Scientific Research Project of the Department of Education of Hunan Province

Zitieren

APA

Yue, J., Yin, Y., Feng, X., Xu, J., Li, Y., Li, T., Liang, S., He, X., Liu, Z., & Wang, Y. (2024). Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments. International Journal of Molecular Sciences, 25(15), 8284. https://doi.org/10.3390/ijms25158284

Vancouver

Yue J, Yin Y, Feng X, Xu J, Li Y, Li T, et al. Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments. International Journal of Molecular Sciences. 2024;25(15):8284. doi:10.3390/ijms25158284

BibTeX
@article{Yue2024,
  author = {Yue, Jianda and Yin, Yekui and Feng, Xujun and Xu, Jiawei and Li, Yaqi and Li, Tingting and Liang, Songping and He, Xiao and Liu, Zhonghua and Wang, Ying},
  title = {Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {15},
  pages = {8284},
  doi = {10.3390/ijms25158284}
}
Kostenlos starten →